✦ LIBER ✦

Phase 2 study of the combination of merimepodib with peginterferon-α2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C

✍ Scribed by Patrick Marcellin; Yves Horsmans; Frederik Nevens; Jean-Didier Grange; Jean-Pierre Bronowicki; Denis Vetter; Susan Purdy; Varun Garg; Leif Bengtsson; Lindsay McNair; John Alam

Book ID: 116651364
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 146 KB
Volume: 47
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2007.03.028

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination Therapy with Interferon-α2b,

Combination Therapy with Interferon-α2b, Ribavirin, and Amantadine in Chronic Hepatitis C Nonresponders to Interferon and Ribavirin

✍ Paul J. Thuluvath; Hemant Pande; Joyce Maygers 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 29 KB

Effectiveness of peginterferon alfa-2b/r

Effectiveness of peginterferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting

✍ N. Terreni; G. Mandelli; G. Spinzi; G. Minoli 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 112 KB

Studies of Therapy with Thymosin α1 in C

Studies of Therapy with Thymosin α1 in Combination with Pegylated Interferon α2a and Ribavirin in Nonresponder Patients with Chronic Hepatitis C

✍ ROBERTO CAMERINI; ALESSIA CIANCIO; ALFONSO DE ROSA; MARIO RIZZETTO 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

Weight-based high- and low-dose ribaviri

Weight-based high- and low-dose ribavirin in combination with peginterferon α-2b therapy for genotype 2 chronic hepatitis C: A randomized trial

✍ Tatehiro Kagawa; Sei-ichiro Kojima; Koichi Shiraishi; Shinji Takashimizu; Naruhi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB

1209 Triple therapy compared to standard

1209 Triple therapy compared to standard Pegylated interferon alfa 2B + weight based ribavirin for previous nonresponders and relapsers with chronic hepatitis C

✍ LAWITZ, E; CANTU, N; DAVIS, M; AFDHAL, N; CURRY, M; MAILLIARD, M; ADAMS, F; TSAI 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

492 A phase II, placebo-controlled study

492 A phase II, placebo-controlled study of merimepodib (XV-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin

✍ P. Marcellin; Y. Horsmans; F. Nevens; J.D. Grange; J.P. Bronowicki; D. Vetter; R 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 63 KB